INTRODUCTION {#S5}
============

Vitamin B12 (B12) in plasma is bound to two distinct transport proteins, haptocorrin and transcobalamin (TC) ([@R6]; [@R12]). Of these two proteins, only TC is known to play a role in both B12 absorption and cellular delivery. Dietary B12 is bound to TC in the ileal enterocyte and the TC-B12 complex (holoTC) enters the circulation. The circulating holoTC binds a specific TC receptor that is found on all tissues and is taken into the cell through endocytosis of the holoTC-receptor complex ([@R35]). Thus, holoTC represents the fraction of total plasma B12 available for uptake into tissue. Accordingly, holoTC is considered to be a potential indicator of B12 status both independently and in conjunction with total B12 and other biochemical indicators of status ([@R40]; [@R36]; [@R31]; [@R16]; [@R26]; [@R9]).

Several single nucleotide polymorphisms have been identified in the TC gene (gene designation: TCN2) ([@R20]; [@R29]; [@R30]; [@R1]). The most common is a cytosine-to-guanine substitution at base position 776 of the genomic DNA sequence (776C\>G). This substitution encodes for arginine in place of proline at codon 259 of the amino acid sequence. It is unclear if this amino acid substitution affects the structure and function of the protein ([@R29]; [@R30]; [@R1]; [@R45]). The prevalence of the homozygous variant form of TC (776GG) is high, with reported estimates in different populations ranging from 3--42% (Bowan *et al.*, 2004; [@R13]), which has led investigators to assess its influence on indicators of B12 status. Typically, no significant difference is found in total serum B12 concentrations among the TC 776 genotypes. In contrast, the 776GG variant has consistently been associated with lower serum or CSF levels of holoTC compared to the homozygous reference variant (776CC) ([@R1]; [@R43]; [@R24]; [@R47]; [@R42]; [@R27]). The 776GG variant has also been associated with higher methylmalonic acid, a metabolite that becomes elevated in B12 deficiency ([@R27]; [@R8]), a lower percentage of total B12 bound to TC (holoTC/B12 ratio) ([@R27]), and lower concentrations of TC with no B12 bound (apoTC) ([@R29]; [@R30]; [@R1]).

Homocysteine, an independent risk factor for vascular disease and related disorders ([@R37]), is elevated in B12 deficiency. It has been reported that individuals heterozygous for the TC 776 variant (776CG) have higher homocysteine concentrations than individuals homozygous for either the reference or variant forms (Namour *et al.*, [@R28]). This remains to be confirmed, however, and more typically no difference in homocysteine levels is observed among the TC genotypes ([@R1]; [@R42]; [@R27]; [@R8]; [@R25]; [@R46]). A notable exception is the observation by [@R21] of a significant interaction between total B12 concentrations and TC genotype; the 776CC reference was associated with lower total plasma homocysteine than the 776GG variant when total B12 was greater than 300 pmol/L. This suggests that the association between B12 concentration and homocysteine is modified by TC 776 genotype and that plasma homocysteine concentrations may be more responsive to dietary B12 or B12 supplements in carriers of the 776CC reference compared with carriers of the 776GG variant.

In the present study, we examined associations between TC 776 genotype and indicators of B12 status in a cohort of community-dwelling older Hispanics participating in the Sacramento Area Latino Study on Aging (SALSA). We also determined if TC 776 genotype serves as an effect modifier of the associations between indicators of B12 status and homocysteine and methylmalonic acid concentrations.

MATERIALS AND METHODS {#S6}
=====================

Subjects {#S7}
--------

The original SALSA study population consisted of a representative sample of community-dwelling older adults (age ≥60y) of Latino ancestry residing in Sacramento, CA, and surrounding Northern California communities (n=1789). Subjects were recruited over a period of 18 months beginning in February 1998. The details of sampling and recruitment have been described elsewhere ([@R44]; [@R15]). Approximately five years after initial recruitment, additional blood samples were collected from 834 subjects and made available for genomic DNA isolation and genotyping. Of these 834, baseline holoTC and total B12 measures were available from 554 subjects for the present study. Subject recruitment and study procedures for the SALSA study were approved by the Human Subjects Review Committee at the University of California, Davis, and written informed consent was obtained from all study participants.

Sample Processing and Analysis {#S8}
------------------------------

Fasting blood samples were collected from all subjects during home visits. The blood was transported on ice to the University of California Davis Medical Center Clinical Laboratory for processing within 4 h of collection. Plasma and serum were isolated and stored at −80 °C until analysis. Total plasma vitamin B12 concentrations were determined by radioassay Quantaphase II; BioRad Diagnostics, Hercules, CA); plasma holoTC by monoclonal antibody capture assay (HoloTC RIA; Axis-Shield, Oslo, Norway); plasma methylmalonic acid by tandem mass spectrometry at ARUP Laboratories, Salt Lake City, Utah ([@R19]); total plasma homocysteine by HPLC with post-column fluorescence detection ([@R10]); red blood cell (RBC) folate by automated chemiluminescence assay (ACS 180: Chiron Diagnostics now Siemens Healthcare Diagnostics\], Tarrytown, NY); and serum creatinine by the Jaffe rate reaction method using a SYNCHRON LX20 instrument (Beckman Coulter, Fullerton, CA). Inter-assay coefficients of variation for each of the assays are: total B12, 4.7%; holoTC, 5.7%; homocysteine, 4.2%; methylmalonic acid, 5.8%; RBC folate, 10%; and creatinine 3.3%. Cutoff values for low (deficient) or elevated plasma concentrations used in this study were: total B12 \<156 pmol/L (reference value used by the UC Davis Medical Center Clinical Laboratory, Sacramento, CA, based on 100% specificity for clinically diagnosed B12 deficiency); holoTC \<35 pmol/L ([@R16]; [@R22]); homocysteine \>13 µmol/L ([@R17]); and methylmalonic acid \>350 nmol/L ([@R7]).

DNA was isolated from EDTA whole blood using QIAamp DNA Blood Maxi Kits (Qiagen, Valencia, CA). TC 776 genotype was determined by polymerase chain reaction (PCR), using an Eppendorf Mastercycler (Brinkmann, Westbury, NY), and restriction enzyme digest as previously published ([@R27]). The PCR protocol was modified to shorten the assay time as follows: 1) bringing of lid temperature to 102 °C; 2) initial denaturation (94 °C, minutes); 3) 34 cycles of denaturation (94 °C, 1 minute), annealing (64 °C, 1 minute), and extension (72 °C, 1 minute); 4) final extension (72 °C, 7 minutes).

Statistical Analyses {#S9}
--------------------

TC genotype and allele frequencies with Clopper-Pearson exact 95% confidence intervals were calculated. Chi-square analysis was used to determine if the TC genotypes were in Hardy-Weinberg equilibrium. Mean metabolite values were compared among the TC genotypes using Scheffe's test. Sex distribution and percentage of subjects with low or high metabolite levels were compared among the TC genotypes by chi-square analysis. Interactive effects of TC genotype and total B12 (nominally divided into groups of \< and ≥156 pmol/L) and holoTC (nominally divided into groups \< and ≥35 pmol/L) on homocysteine and methylmalonic acid levels were assessed by 2-factor ANOVA. Due to the small number of subjects in the 776GG group, the 776CG and 776GG genotypes were combined into one group and compared with the 776CC reference group for the 2-factor ANOVA. Because the distributions of homocysteine and methylmalonic acid did not conform to a Gaussian distribution (tailing toward higher values), these variables were natural log transformed before analysis. In secondary analyses, logistic regression was carried out to determine the odds ratios (95% C.I.) for elevated homocysteine (\>13 µmol/L) for the 776CC group compared with the combined 776CG/776GG group, for total B12 \<156 pmol/L compared with total B12 ≥156 pmol/L, for holoTC \<35 pmol/L compared with holoTC ≥35 pmol/L, and for the interactions between TC 776 genotype and total B12 or holoTC. For both the 2-factor ANOVA and logistic regression analyses, we controlled for confounding by age, sex, RBC folate, and creatinine. Statistical significance was defined as p\<0.05.

RESULTS {#S10}
=======

The characteristics of the study sample are presented in [Table 1](#T1){ref-type="table"}. The distribution of the TC polymorphism (with 95% C.I.) was: 776CC (homozygous reference), 41.3% (37.2, 45.6); 776CG (heterozygotes), 47.1% (42.9, 51.4); and 776GG (homozygous variant), 11.6% (9.0, 14.5). The allele frequencies (95% C.I.) for 776C and 776G were 0.65 (0.62, 0.68) and 0.35 (0.32, 0.38), respectively. The distribution is within Hardy-Weinberg equilibrium (*X*^2^=0.64, p=0.42). No significant difference in total B12 was observed among the genotypes. Mean holoTC in the 776GG group was lower than in the 776CC group, but the difference did not reach statistical significance (p=0.09). The difference in mean holoTC/B12 ratio was, however, significantly lower in the 776GG group compared with the 776CC group (p=0.01). There were no significant differences in homocysteine or methylmalonic acid levels among the genotypes, nor were there significant differences among the genotypes in percentages of subjects with low total B12 (\<156 pmol/L), low holoTC (\<35 pmol/L), high methylmalonic acid (\>350 nmol/L), or high homocysteine (\>13 µmol/L).

By 2-factor ANOVA, significant interactions between TC genotype and total B12 (p=0.04) and between TC genotype and holoTC (p=0.02) on homocysteine were observed. Subsequent analyses for subjects divided by low and high total B12 (\< or ≥156 pmol/L) revealed that homocysteine was higher in the 776CC group compared with the combined 776CG/776GG group for those subjects with low total B12, though the difference did not reach statistical significance (p=0.08). No difference was observed in homocysteine between the genotype groups for subjects with high total B12 ([Figure 1](#F1){ref-type="fig"}). For subjects divided by low and high holoTC (\< or ≥35 pmol/L), homocysteine was significantly higher in the 776CC group compared with the combined 776CG/776GG group for those subjects with low holoTC (p=0.02), while no difference was observed between the genotype groups for subjects with high holoTC ([Figure 2](#F2){ref-type="fig"}). No significant interactive effects were observed between TC genotype and either total B12 or holoTC on methylmalonic acid concentrations (data not shown).

Multivariate logistic regression analyses were performed to assess the risk of having hyperhomocysteinemia (\>13 µmol/L) between the TC 776 genotype groups, between subjects with low and high total B12 or low and high holoTC, and for the interaction between TC 776 genotype and total B12 or holoTC. For the model including low and high total B12 as an independent variable ([Table 2, Model 1](#T2){ref-type="table"}), the interaction between genotype and total B12 was significant (p=0.04), and subjects with low total B12 (p\<0.001) or who were homozygous for the 776CC reference (p=0.05) had elevated odds ratios for hyperhomocysteinemia. Similarly, for the model including low and high holoTC as an independent variable ([Table 2, Model 2](#T2){ref-type="table"}), the interaction between genotype and holoTC was significant (p=0.03), and subjects with low total holoTC (p\<0.001) or who were homozygous for the 776CC reference (p=0.03) had elevated odds ratios for hyperhomocysteinemia.

DISCUSSION {#S11}
==========

The prevalence of the homozygous TC 776GG variant in the SALSA study sample was 11.6%, compared to 17.6% in a group of 239 Hispanic blood donors from the Mexico City area ([@R13]). The reason for the difference in prevalence between these two study samples of the same ethnicity is unclear, but the latter study included subjects age 20--60y, while in SALSA they were ≥60y. In addition, it is not known whether these Hispanic cohorts are genetically similar. Reported prevalence of the 776GG variant in other ethnic groups ranges from \~3% in West Africans to \~11% in Italian Caucasians; \~13% in Afro-Americans; \~13% in Brazilians; \~20% in French, Scandinavian, and American Caucasians; and \~42% in ethnic Hans from Central China ([@R4]; [@R13]; [@R27]; [@R3]; [@R33]; [@R2]). [@R13] have proposed that environmental factors, in particular malaria, may have imposed selective pressures that contribute to the wide variation in prevalence of the TC 776 polymorphism in different populations.

There was no difference among the genotypes in total B12 concentration, consistent with previous reports ([@R30]; [@R47]; [@R42]; [@R27]; [@R25]; [@R48]). HoloTC was lower in the 776GG homozygous variant group, also consistent with reports by others ([@R1]; [@R43]; [@R24]; [@R47]; [@R42]; [@R27]), although the difference in the SALSA study sample did not reach statistical significance. There was a significant difference among the genotypes in holoTC/B12 ratio, an observation we made previously in a study of primarily Caucasian individuals ([@R27]). It has been proposed that the TC 776 polymorphism may affect the intra-molecular folding of the transcobalamin protein resulting in reduced affinity for B12, though there is some disagreement on this issue ([@R29]; [@R30]; [@R1]; [@R45]). The lower holoTC/B12 ratio observed in individuals with the 776GG homozygous variant suggests that the G allele may indeed encode a protein with a significantly lower affinity for B12 than that encoded by the C allele. This may have important clinical implications based on our published finding that the holoTC/B12 ratio is associated with cognitive impairment in the SALSA population, particularly in those with elevated depressive symptoms ([@R9]). A possible influence of TC genotype on the binding of holoTC to the TC receptor is also a potential consideration. This may now be investigated since the TC receptor has been cloned recently ([@R35]).

The most novel findings in this study are the significant interactions between TC genotype and indicators of B12 status (total B12 and holoTC) on homocysteine concentrations. Differences in homocysteine were observed between the genotypes only in those subjects with low total B12 or low holoTC. Mean homocysteine concentrations and odds ratios for hyperhomocysteinemia were higher for 776CC homozygotes compared with carriers of the G allele (776CG and 776GG combined) when total B12 or holoTC were low. [@R21] made a similar, though not identical observation: individuals homozygous for the reference allele with total B12 ≥300 pmol/L had lower homocysteine than those with the variant allele. An interaction between TC genotype and holoTC on homocysteine, however, was not assessed in this study ([@R21]). Together these findings suggest that TC 776 genotype is an effect modifier of the association between B12 status and homocysteine concentration, and that in those homozygous for the C allele, homocysteine levels may be more responsive to dietary B12 or B12 supplementation than in those with one or two G alleles. This may be an important consideration when evaluating the effect of B12 supplements or other modes of B12 intervention on plasma homocysteine. It is also important to note that since higher homocysteine was observed in the 776CC reference group when B12 status was low, the influence of the polymorphism on homocysteine levels may be more complicated than simply reduced affinity of TC for B12 caused by the presence of the G allele, as discussed above. It could be argued that the G allele is actually protective rather than deleterious when B12 status is low, which perhaps explains the relatively high prevalence of the variant form observed in different populations.

No significant difference was observed in methylmalonic acid concentrations among the TC genotypes, nor was a significant interaction detected between TC genotype and total B12 or holoTC on methylmalonic acid. This differs from our previous study in which we observed higher methylmalonic acid concentrations in the TC 776GG homozygotes compared with the TC 776CC homozygotes ([@R27]). This discrepancy between the two studies may be due to genetic, dietary or other environmental differences between Caucasian and Hispanic populations.

The influence of the TC 776 polymorphism on risk of clinical B12 deficiency remains to be determined. There are reports of direct associations between the 776 G allele and neural tube defects ([@R34]; [@R14]), spontaneous abortion ([@R46]), cleft palate/lip ([@R23]), and autism ([@R18]). Other studies did not confirm the associations with neural tube defects and spontaneous abortion ([@R1]; [@R39]; [@R5]; [@R32]). One report found that TC genotype may influence the age of onset of Alzheimer's disease ([@R24]). TC genotype was not associated with congenital heart defects ([@R41]) and thrombosis ([@R48]; [@R33]). Notably, in none of these studies was the interaction between TC genotype and indicators of B12 status (i.e. total B12 or holoTC) on clinical risk considered. TC genotype might be an effect modifier of the associations between markers of B12 status and clinical disorders, as suggested by our finding of a significant interaction between holoTC and TC genotype on homocysteine concentrations in the SALSA study.

A final consideration is that our present findings were made in a population exposed to folic acid fortification, fully implemented in the United States as of January 1998 with the purpose of reducing the incidence of neural tube defects. We have shown elsewhere that in the SALSA study sample the prevalence of folate deficiency is very low (\~1%) and that vitamin B12 status is now the dominant nutritional determinant of homocysteine levels ([@R11]), at least in older adults. The present study suggests that in a folic acid fortified population, TC 776 genotype is an effect modifier of the associations between total B12 or holoTC concentrations and the risk of hyperhomocysteinemia, a condition which is associated with vascular disorders, cognitive dysfunction and dementia, birth defects, and osteoporosis [@R37], [@R38]).
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![Interaction between total B12 and transcobalamin genotype on homocysteine. ANOVA for interaction between TC genotype (grouped as 776 CC and 776CG + 776GG) and total B12 (grouped as \< and ≥ 156 pmol/L) was significant (p=0.04). Post-hoc comparisons of group means were made using Scheffe's test, with controlling for age, sex, red blood cell folate, and creatinine. Bars represent geometric means with 95% confidence intervals.](nihms169860f1){#F1}

![Interaction between holotranscobalamin (holoTC) and TC genotype on homocysteine. ANOVA for interaction between TC genotype (grouped as 776 CC and 776CG + 776GG) and holoTC (grouped as \< and ≥ 35 pmol/L) was significant (p=0.02). Post-hoc comparisons of group means were made using Scheffe's test, with controlling for age, sex, red blood cell folate, and creatinine. Bars represent geometric means with 95% confidence intervals.](nihms169860f2){#F2}

###### 

Characteristics of study sample grouped by transcobalamin 776 genotype[\*](#TFN1){ref-type="table-fn"}

                                          TC 776 Genotype                         
  -------------------------- ------------ ------------------- ------------------- ----------------------------------------------
  N                          554          229                 261                 64
    Frequency % (95% C.I.)                41.3 (37.2, 45.6)   47.2 (42.9, 51.4)   11.6 (9.0, 14.5)
  Sex (% female)             60           63                  57                  64
  Age (y)                    69 ± 6       69 ± 6              70 ± 6              69 ± 6
  Vitamin B12 (pmol/L)       314 ± 128    316 ± 142           312 ± 121           316 ± 107
    B12 \<156 pmol/L (%)     8.5          9.6                 7.7                 7.8
  HoloTC (pmol/L)            78 ± 32      80 ± 33             77 ± 33             70 ± 27
    HoloTC \<35 pmol/L (%)   8.5          8.3                 9.6                 4.7
  HoloTC/B12 Ratio (%)       25.7 ± 0.1   26.5 ± 0.1          25.6 ± 0.1          22.8 ± 0.1[\*\*](#TFN2){ref-type="table-fn"}
  MMA (nmol/L)               239 ± 562    286 ± 841           204 ± 182           207 ± 134
    MMA \>350 (%)            10.3         10.4                9.0                 16.7
  Hcy (μmol/L)               10.4 ± 6.4   10.8 ± 9.1          10.2 ± 3.3          9.7 ± 3.3
    Hcy \>13 μmol/L (%)      12.3         12.7                12.6                9.4
  RBC Folate (ng/mL)         509 ± 157    505 ± 153           513 ± 160           509 ± 158
  Creatinine (mg/dL)         0.8 ± 0.3    0.8 ± 0.3           0.8 ± 0.2           0.8 ± 0.2

Values are means ± SD, except for N, frequency, sex, and percentage below or above cutoff values.

Significantly different from 776CC group by Scheffe's test (p=0.04).

[Abbreviations]{.ul}: TC, transcobalamin; HoloTC, holotranscobalamin; MMA, methylmalonic acid; Hcy, homocysteine; RBC, red blood cell.

###### 

Odds ratios for elevated homocysteine (\>13 μmol/L)[\*\*](#TFN4){ref-type="table-fn"}

  Model                             OR (95% C.I.)       p-value
  --------------------------------- ------------------- ---------
  [Model 1]{.ul}:                                       
   776CC vs 776CG+776GG             18.8 (1.04, 339)    0.05
   Total B12 \<156 vs ≥156 pmol/L   220 (14.7, 3310)    \<0.001
   TC Genotype \* Total B12         5.41 (1.08, 27.0)   0.04
  [Model 2]{.ul}:                                       
   776CC vs 776CG+776GG             27.9 (1.33, 584)    0.03
   HoloTC \<35 vs ≥35 pmol/L        227 (13.7, 3760)    \<0.001
   TC Genotype \* HoloTC            5.99 (1.14, 31.6)   0.03

Odds ratios and 95% confidence intervals were calculated controlling for confounding by age, sex, red blood cell folate, and creatinine.

[Abbreviations]{.ul}: OR, odds ratio; C.I., confidence interval; TC, transcobalamin; HoloTC, holotranscobalamin; 776CC, transcobalamin homozygous wild-type; 776CG, transcobalamin heterozygotes; 776GG, transcobalamin homozygous variant.
